Atrial natriuretic peptide during mineralocorticoid escape in the human

R. S. Zimmerman, Brooks Sayre Edwards, T. R. Schwab, D. M. Heublein, John C Jr. Burnett

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The relationship between plasma atrial natriuretic peptide (ANP) and mineralocorticoid escape was examined in six normal men (age, 20-32 yr) treated with 0.4 mg/day fludrocortisone acetate for 9-14 days. Urinary sodium excretion decreased from 162 ± 15 (SEM) meq/24 h before to 97 ± meq/24 h during fludrocortisone acetate administration (P < 0.05). Despite continued fludrocortisone acetate administration, sodium excretion subsequently returned to baseline (escape). Plasma ANP increased from 33 ± 6 pg/ml (control) to 55 ± 14 pg/ml on the first day of escape (P < 0.05). Escape was associated with a decrease in PRA from 0.90 ± 0.22 (control) to 0.26 ± 0.08 ng/ml·h (escape, P < 0.05). The escape phenomenon was not associated with a significant change in mean arterial pressure or glomerular filtration rate. This study demonstrates that mineralocorticoid escape is temporally related to a significant increase in circulating ANP.

Original languageEnglish (US)
Pages (from-to)624-627
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume64
Issue number3
StatePublished - 1987

Fingerprint

Mineralocorticoids
Atrial Natriuretic Factor
Sodium
Plasmas
Glomerular Filtration Rate
Arterial Pressure
Scanning electron microscopy
fludrocortisone acetate

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Atrial natriuretic peptide during mineralocorticoid escape in the human. / Zimmerman, R. S.; Edwards, Brooks Sayre; Schwab, T. R.; Heublein, D. M.; Burnett, John C Jr.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 64, No. 3, 1987, p. 624-627.

Research output: Contribution to journalArticle

@article{98e5d441e57e4b68a7370fe335bbd341,
title = "Atrial natriuretic peptide during mineralocorticoid escape in the human",
abstract = "The relationship between plasma atrial natriuretic peptide (ANP) and mineralocorticoid escape was examined in six normal men (age, 20-32 yr) treated with 0.4 mg/day fludrocortisone acetate for 9-14 days. Urinary sodium excretion decreased from 162 ± 15 (SEM) meq/24 h before to 97 ± meq/24 h during fludrocortisone acetate administration (P < 0.05). Despite continued fludrocortisone acetate administration, sodium excretion subsequently returned to baseline (escape). Plasma ANP increased from 33 ± 6 pg/ml (control) to 55 ± 14 pg/ml on the first day of escape (P < 0.05). Escape was associated with a decrease in PRA from 0.90 ± 0.22 (control) to 0.26 ± 0.08 ng/ml·h (escape, P < 0.05). The escape phenomenon was not associated with a significant change in mean arterial pressure or glomerular filtration rate. This study demonstrates that mineralocorticoid escape is temporally related to a significant increase in circulating ANP.",
author = "Zimmerman, {R. S.} and Edwards, {Brooks Sayre} and Schwab, {T. R.} and Heublein, {D. M.} and Burnett, {John C Jr.}",
year = "1987",
language = "English (US)",
volume = "64",
pages = "624--627",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "3",

}

TY - JOUR

T1 - Atrial natriuretic peptide during mineralocorticoid escape in the human

AU - Zimmerman, R. S.

AU - Edwards, Brooks Sayre

AU - Schwab, T. R.

AU - Heublein, D. M.

AU - Burnett, John C Jr.

PY - 1987

Y1 - 1987

N2 - The relationship between plasma atrial natriuretic peptide (ANP) and mineralocorticoid escape was examined in six normal men (age, 20-32 yr) treated with 0.4 mg/day fludrocortisone acetate for 9-14 days. Urinary sodium excretion decreased from 162 ± 15 (SEM) meq/24 h before to 97 ± meq/24 h during fludrocortisone acetate administration (P < 0.05). Despite continued fludrocortisone acetate administration, sodium excretion subsequently returned to baseline (escape). Plasma ANP increased from 33 ± 6 pg/ml (control) to 55 ± 14 pg/ml on the first day of escape (P < 0.05). Escape was associated with a decrease in PRA from 0.90 ± 0.22 (control) to 0.26 ± 0.08 ng/ml·h (escape, P < 0.05). The escape phenomenon was not associated with a significant change in mean arterial pressure or glomerular filtration rate. This study demonstrates that mineralocorticoid escape is temporally related to a significant increase in circulating ANP.

AB - The relationship between plasma atrial natriuretic peptide (ANP) and mineralocorticoid escape was examined in six normal men (age, 20-32 yr) treated with 0.4 mg/day fludrocortisone acetate for 9-14 days. Urinary sodium excretion decreased from 162 ± 15 (SEM) meq/24 h before to 97 ± meq/24 h during fludrocortisone acetate administration (P < 0.05). Despite continued fludrocortisone acetate administration, sodium excretion subsequently returned to baseline (escape). Plasma ANP increased from 33 ± 6 pg/ml (control) to 55 ± 14 pg/ml on the first day of escape (P < 0.05). Escape was associated with a decrease in PRA from 0.90 ± 0.22 (control) to 0.26 ± 0.08 ng/ml·h (escape, P < 0.05). The escape phenomenon was not associated with a significant change in mean arterial pressure or glomerular filtration rate. This study demonstrates that mineralocorticoid escape is temporally related to a significant increase in circulating ANP.

UR - http://www.scopus.com/inward/record.url?scp=0023151131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023151131&partnerID=8YFLogxK

M3 - Article

C2 - 2950127

AN - SCOPUS:0023151131

VL - 64

SP - 624

EP - 627

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 3

ER -